These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37979138)

  • 21. Opioid Use Disorder Treatment Initiation and Continuation: a Qualitative Study of Patients Who Received Addiction Consultation and Hospital-Based Providers.
    Calcaterra SL; Lockhart S; Callister C; Hoover K; Binswanger IA
    J Gen Intern Med; 2022 Aug; 37(11):2786-2794. PubMed ID: 34981359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study.
    Jones BLH; Geier M; Neuhaus J; Coffin PO; Snyder HR; Soran CS; Knight KR; Suen LW
    Harm Reduct J; 2024 Apr; 21(1):80. PubMed ID: 38594721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A qualitative examination of the current management of opioid use disorder and barriers to prescribing buprenorphine in a Canadian emergency department.
    Wiercigroch D; Hoyeck P; Sheikh H; Hulme J
    BMC Emerg Med; 2021 Apr; 21(1):48. PubMed ID: 33858328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of an injectable monthly extended-release buprenorphine program in a low-barrier specialty addiction medicine clinic.
    Heil J; Salzman M; Hunter K; Baston KE; Milburn C; Schmidt R; Haroz R; Ganetsky VS
    J Subst Use Addict Treat; 2024 Jan; 156():209183. PubMed ID: 37879433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
    Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR
    Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Buprenorphine Continuation During Critical Illness Associated With Decreased Inpatient Opioid Use in Individuals Maintained on Buprenorphine for Opioid Use Disorder in a Retrospective Study.
    Quaye A; Wampole C; Riker RR; Seder DB; Sauer WJ; Richard JM; Craig WY; Gagnon DJ
    J Clin Pharmacol; 2023 Sep; 63(9):1067-1073. PubMed ID: 37204408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experiences with an addiction consultation service on care provided to hospitalized patients with opioid use disorder: a qualitative study of hospitalists, nurses, pharmacists, and social workers.
    Callister C; Lockhart S; Holtrop JS; Hoover K; Calcaterra SL
    Subst Abus; 2022; 43(1):615-622. PubMed ID: 34666634
    [No Abstract]   [Full Text] [Related]  

  • 29. Buprenorphine precipitated opioid withdrawal: Prevention and management in the ED setting.
    Spadaro A; Long B; Koyfman A; Perrone J
    Am J Emerg Med; 2022 Aug; 58():22-26. PubMed ID: 35623179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 31. Buprenorphine for Chronic Pain Management: a Narrative Review.
    Vu PD; Bansal V; Chitneni A; Robinson CL; Viswanath O; Urits I; Kaye AD; Nguyen A; Govindaraj R; Chen GH; Hasoon J
    Curr Pain Headache Rep; 2023 Dec; 27(12):811-820. PubMed ID: 37897592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-Dose Initiation of Buprenorphine: A Narrative Review.
    Edinoff AN; Fahmy OH; Spillers NJ; Zaheri AR; Jackson ED; De Witt AJ; Wenger DM; Cornett EM; Skidmore KL; Kaye AM; Kaye AD
    Curr Pain Headache Rep; 2023 Jul; 27(7):175-181. PubMed ID: 37083890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences in buprenorphine prescribing readiness among primary care professionals with and without X-waiver training in the US.
    Franz B; Dhanani LY; Hall OT; Brook DL; Simon JE; Miller WC
    Harm Reduct J; 2023 Dec; 20(1):180. PubMed ID: 38129903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids.
    Weimer MB; Herring AA; Kawasaki SS; Meyer M; Kleykamp BA; Ramsey KS
    J Addict Med; 2023 Nov-Dec 01; 17(6):632-639. PubMed ID: 37934520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-dose Buprenorphine Initiation in Hospitalized Adults With Opioid Use Disorder: A Retrospective Cohort Analysis.
    Button D; Hartley J; Robbins J; Levander XA; Smith NJ; Englander H
    J Addict Med; 2022 Mar-Apr 01; 16(2):e105-e111. PubMed ID: 34001775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic.
    Currie JM; Schnell MK; Schwandt H; Zhang J
    JAMA Netw Open; 2021 Apr; 4(4):e216147. PubMed ID: 33856474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State.
    Banta-Green CJ; Owens MD; Williams JR; Sears JM; Floyd AS; Williams-Gilbert W; Kingston S
    Addict Sci Clin Pract; 2022 Jul; 17(1):34. PubMed ID: 35799210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
    Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
    JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies.
    De Aquino JP; Parida S; Avila-Quintero VJ; Flores J; Compton P; Hickey T; Gómez O; Sofuoglu M
    Drug Alcohol Depend; 2021 Nov; 228():109097. PubMed ID: 34601272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treating opioid use disorder with rapid micro induction technique of sublingual buprenorphine/naloxone in an outpatient setting-a case report.
    Martell JP; Konakanchi JS; Sethi R
    J Addict Dis; 2022; 40(3):439-443. PubMed ID: 35072589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.